Advertisement
Table 2 Descriptions of complications in the study group of the included studies
| Author, year | Enrolled Sample number (G1/G2) | Descriptions of complications in study group | Conclusion |
|---|---|---|---|
| Hirasawa, 2018 [14] | 45/45 | No complication including surgical site infection, wound complications, prolonged numbness or weakness, or allergy to the medication | No difference |
| Ban WR,2017 [5] | 43/43 | No mention | N/A |
| Villatte, 2016 [6] | 75/75 | Wound septic complication (2 hips, treatment group) | No difference |
| Hofstad, 2015 [10] | 55/54 | No mention | N/A |
| den Hartog, 2015 [11] | 25/25 | Dizziness, hypotension and retention of urine | No difference |
| Zoric, 2014 [12] | 29/29 | Nausea and vomiting | No difference |
| Dobie, 2012 [15] | 46/46 | Hypotension, chest pain, dural leak | No difference |
| Murphy, 2012 [7] | 45/46 | Urinary retention | No difference |
| Andersen, 2011 [16] | 12/12 | No clinical side effect, including cardiac and hemodynamic changes | No difference |
| Lunn, 2011 [13] | 60/60 | Quadriceps muscle palsy | No difference |
| Liu, 2011 [8] | 40/40 | Hemodynamic change, nausea and vomiting, urinary retention, respiratory depression, rash, and deep vein thrombosis | No difference |
| Busch, 2010 [9] | 32/31 | Wound blister, prominent suture trimming and deep vein thrombosis (4 hips, 3 in the treatment group and 1 in the control group) | No difference |
